Hair and Nail Changes during Long-Term Therapy with Ibrutinib for Chronic Lymphocytic Leukemia

IMPORTANCE: Ibrutinib (Imbruvica(®)), a Bruton tyrosine kinase (BTK) inhibitor, is a new targeted agent approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia (CLL), mantle cell lymphoma, and Waldenström macroglobulinemia. Ibrutinib is overall well-tolerate...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:JAMA Dermatol
Päätekijät: Bitar, Carole, Farooqui, Mohammed Z.H., Valdez, Janet, Saba, Nakhle S., Soto, Susan, Bray, Amanda, Marti, Gerald, Wiestner, Adrian, Cowen, Edward W.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6415534/
https://ncbi.nlm.nih.gov/pubmed/26982511
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamadermatol.2016.0225
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia